News Search Results
Jul 30, 2024, 17:30 ET Telehealth Market size is set to grow by USD 368.7 billion from 2024-2028, Increasing cases of chronic diseases boost the market, Technavio
store-and-forward, remote patient monitoring, and specialized services like pathology, neurology, dermatology, surgery, gynecology, orthopedics, and ophthalmology. Digital health companies are focusing on AI adoption, web-based delivery mode, and real-time patient monitoring to cater to the growing demand
More news about: Technavio
Jul 30, 2024, 08:00 ET ViaLase Receives CE Mark for First Femtosecond Laser for the Treatment of Glaucoma, the ViaLase® Laser
Teleon Surgical (Germany and Austria). Each organization has deep ophthalmology experience and an established commercial presence in their markets. These strategic partnerships will allow for a timely and efficient rollout of
More news about: ViaLase, Inc.
Jul 30, 2024, 08:00 ET ViaLase Receives CE Mark for First Femtosecond Laser for the Treatment of Glaucoma, the ViaLase® Laser
Teleon Surgical (Germany and Austria). Each organization has deep ophthalmology experience and an established commercial presence in their markets. These strategic partnerships will allow for a timely and efficient rollout of
More news about: ViaLase, Inc.
Jul 30, 2024, 08:00 ET ViaLase recibe la marca CE para el primer láser de femtosegundo para el tratamiento del glaucoma
2.Tham YC, Xiang L, et al. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis. Ophthalmology 2014; 121(11): 2081-2090.
More news about: ViaLase, Inc.
Jul 30, 2024, 07:59 ET Piramal Pharma Solutions Achieves Revenue Threshold on Innovation Work
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics
More news about: Piramal Pharma Solutions
Jul 30, 2024, 07:55 ET Piramal Pharma Solutions Achieves Revenue Threshold on Innovation Work
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics
More news about: Piramal Pharma Solutions
Jul 29, 2024, 10:30 ET Prefilled Syringes Market worth $13.1 billion by 2030 driven by Rising Chronic Illness Rates | MarketsandMarkets™
Market The prefilled syringe market is divided by application into diabetes, rheumatoid arthritis, anaphylaxis, cancer, thrombosis, ophthalmology, and others. In 2023, the cancer segment is projected to hold the largest market share. This is driven by the increasing global prevalence of cancer,
More news about: MarketsandMarkets
Jul 29, 2024, 07:30 ET Priovant Therapeutics Announces Completion of Enrollment in Global Phase 3 Study Evaluating Brepocitinib in Dermatomyositis (VALOR)
macular edema accepted as oral presentations at the upcoming EURETINA Congress September 19-22 and American Academy of Ophthalmology (AAO) annual meeting October 18-21. Priovant expects to share 52-week top-line results from the NEPTUNE study and
More news about: Priovant Therapeutics
Jul 29, 2024, 07:05 ET Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ
approvals.SMO business continued steady growth, maintaining significant advantages in multiple therapeutic areas (cardiovascular disease, ophthalmology, rheumatology, central nervous system, endocrinology, medical aesthetics and rare tumors, etc.).WuXi
More news about: WuXi AppTec
Jul 29, 2024, 04:17 ET Nucleic Acid Aptamers Market to Reach USD 1.2 Billion by 2034: Unique Applications in Drug Delivery & Personalized Medicine Driving Growth | TMR
market for nucleic acid aptamers is slated to expand nearly 5x.By indication, nucleic acid aptamers are expected to be used extensively for ophthalmology.DNA aptamers are anticipated to remain in high demand throughout the forecast period.Disease recognition to emerge as an important
More news about: Transparency Market Research
Jul 26, 2024, 10:22 ET U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharmaceutical Industries Limited
Jul 26, 2024, 07:00 ET HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update
endocrine, circulatory, and urologic diseases for over 50 years. HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. One of its lead pipeline assets,
More news about: HanAll Biopharma
Jul 26, 2024, 06:54 ET Piramal Pharma Limited Announces Consolidated Results for Q1FY25
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Jul 26, 2024, 06:45 ET Piramal Pharma Limited Announces Consolidated Results for Q1FY25
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Jul 25, 2024, 21:31 ET Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced a strategic partnership with WeComput to jointly advance the construction and improvement of Innovent
More news about: Innovent Biologics
Jul 25, 2024, 20:09 ET U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharmaceutical Industries Limited
Jul 25, 2024, 14:07 ET Stuart Therapeutics, Inc. Announces Key Addition to its Executive Team
developing an extremely interesting therapeutic platform that targets diseased tissues in a novel way compared to conventional therapeutics for ophthalmology," said Dr. Scheibler. "The company has demonstrated the ability to build viable development programs with a lean, effective team. I'm pleased to
More news about: Stuart Therapeutics
Jul 24, 2024, 20:00 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
("IOP"). Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027." On this news,
More news about: Pomerantz LLP
Jul 24, 2024, 10:00 ET PatientPoint and the American Diabetes Association Collaborate to Highlight Diabetes Education
their health is top of mind." PatientPoint will feature relevant ADA diabetes education via digital devices in primary care, pediatrics and ophthalmology waiting rooms and exam rooms nationwide. New and updated diabetes education will also be provided to healthcare teams via PatientPoint back office
More news about: PatientPoint
Jul 24, 2024, 07:00 ET Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer
within the Roche Group and its affiliates, including Senior Vice President and Head of U.S. Medical Affairs of Genentech and Franchise Head for Ophthalmology. Dr. Baldo succeeds David Fellows, who has served as CEO since Syncona Limited's acquisition of AGTC in
More news about: Beacon Therapeutics
Jul 23, 2024, 08:00 ET Emmes Group partners with Miimansa AI to accelerate adoption of Generative AI in clinical research
partnerships and commercial biopharma. Emmes Group has built industry leading capabilities in cell and gene therapy, vaccines and infectious diseases, ophthalmology, rare diseases, and neuroscience. Today, the company is transforming the future of clinical research, by creating the industry's first native digital
More news about: EMMES
Jul 23, 2024, 08:00 ET Emmes Group partners with Miimansa AI to accelerate adoption of Generative AI in clinical research
partnerships and commercial biopharma. Emmes Group has built industry leading capabilities in cell and gene therapy, vaccines and infectious diseases, ophthalmology, rare diseases, and neuroscience. Today, the company is transforming the future of clinical research, by creating the industry's first native digital
More news about: EMMES
Jul 22, 2024, 03:00 ET SIFI Receives COMP Positive Opinion on Orphan Drug Designation for Polihexanide in Treating Fungal Keratitis
USA and Europe. A potential CRO partner should demonstrate extensive experience in ophthalmology and rare diseases, and a global presence. "As we are preparing to launch AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis
More news about: SIFI S.p.A.
Jul 21, 2024, 20:00 ET Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical trial (DREAMS-1) of mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1
More news about: Innovent Biologics
Jul 19, 2024, 17:55 ET Aesthetic Lasers And Energy Devices Market size is set to grow by USD 2.37 billion from 2024-2028, Increasing global awareness about medical aesthetics to boost the market growth, Technavio
cosmetic surgery centers, and rising healthcare expenditure. Key applications include hair removal, skin rejuvenation, skin tightening, aesthetic ophthalmology, and body contouring. Technologies like radiofrequency, laser-based, and light-based are utilized for hair transplantation, body shaping, facial
More news about: Technavio